Zobrazeno 1 - 10 of 202 pro vyhledávání: '"Dieter Huhn"'
1
Analysis of the p53 and MDM-2 gene in acute myeloid leukemia
Autor: Joachim örtel, Stephen Störkel, Dieter Huhn, Karin Kolbe, Detlef Vogel, Stefan Papadileris, Georg Hess, Barbara Seliger, Cornelia Brendel, Andreas Neubauer, Christoph Huber
Publikováno v: European Journal of Haematology. 57:230-240
The MDM-2 (murine double minute 2) gene codes for a cellular protein that can bind to the p53 tumor suppressor gene product, thereby functioning as a negative regulator of p53. In order to define the role of the MDM-2 gene in the pathogenesis of huma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::687647b935565a4ea3d0550263d8b942
https://doi.org/10.1111/j.1600-0609.1996.tb01369.x
Zobrazit plný text záznamu
2
Growth of the Reh Cell Line in Diffusion Chambers: Evidence for Differentiation Along the T- and B-Cell Pathway
Autor: E. Thiel, H. Rodt, B. Netzel, B. Lau, K. Pachmann, P. Dörmer, Gundula Jäger, Dieter Huhn, S. Thierfelder, L. Böning
Publikováno v: Scandinavian Journal of Haematology. 23:285-292
Cells of the Reh line, originally derived from an ALL of the ‘Non-T, Non-B’ type were cultured in diffusion chambers implanted intraperitoneally into preirradiated CBA mice. At different intervals over a period of 20 d changes in surface characte
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ddd47fc904c9696746b6fbb0360d623a
https://doi.org/10.1111/j.1600-0609.1979.tb02863.x
Zobrazit plný text záznamu
3
Cytochemistry and Membrane Markers in Acute Lymphatic Leukaemia (ALL)
Autor: P. Andreewa, Dieter Huhn, E. Thiel, H. Rodt
Publikováno v: Scandinavian Journal of Haematology. 26:311-320
136 patients suffering from ALL were subdivided into 5 subtypes (C-ALL, C/T-ALL, pre-T-ALL, B-ALL) according to rosetting tests and using specific antisera directed against membrane antigens. In addition, leukaemic blasts of all patients were investi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c11f7efcdaacd4debee345c90e05606
https://doi.org/10.1111/j.1600-0609.1981.tb01667.x
Zobrazit plný text záznamu
5
Treatment options of AIDS-related lymphoma
Autor: Ulrich Mey, Uwe Schlegel, Hendrik Pels, Rudolf Weiss, John Strehl, Ingo G.H. Schmidt-Wolf, Jürgen K. Rockstroh, Dieter Huhn
Publikováno v: Expert Opinion on Pharmacotherapy. 4:1331-1343
Recently, the median survival of patients with AIDS-related lymphoma has changed significantly. This effect is mainly because of changes in the use of antiviral (highly active antiretroviral therapy; HAART) or chemotherapy regimens. Several novel tre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::772646c5d009e983846fb02ab8ae2bb6
https://doi.org/10.1517/14656566.4.8.1331
Zobrazit plný text záznamu
6
Imatinib in Philadelphia chromosome-positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome
Autor: Karl Anton Kreuzer, Philipp le Coutre, Harald Gschaidmeier, Michaela Schwarz, Il-Kang Na, Gerhard Ehninger, Joachim Lupberger, Dieter Huhn, Gökben Baskaynak, Matthias Holdhoff, Christian Schmidt, Witold Prejzner, Uwe Platzbecker
Publikováno v: American Journal of Hematology. 73:249-255
Previous clinical trials with the tyrosine kinase inhibitor imatinib in chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia (CML) resulted in 95% of hematologic and 60% major cytogenetic remissions in patients who failed a pre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::572f279360c4784151b9fe9f21b3ad5b
https://doi.org/10.1002/ajh.10364
Zobrazit plný text záznamu
7
Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia
Autor: Holger Schulz, Wolfgang-Ulrich Knauf, Michael Hallek, Dieter Huhn, Andreas Engert, Saskia K. Klein, Walter-Erich Aulitzky, Marcel Reiser, Volker Diehl, Manfred Hensel, Ute Rehwald, Axel Hinke, Michael Herold
Publikováno v: Blood. 100:3115-3120
This multicenter phase 2 trial investigated safety and efficacy of a new immunochemotherapeutic regimen combining rituximab (R) and fludarabine (F) in patients with fludarabine- and anthracycline-naive chronic lymphocytic leukemia (CLL). The rational
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fb367a578755c633d99e753ece77ae6
https://doi.org/10.1182/blood-2002-03-0972
Zobrazit plný text záznamu
8
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
Autor: Bertold Emmerich, Christian Peschel, Anthony D. Ho, Stefanie Srock, Wolfgang Knauf, Christoph von Schilling, Ute Riedel, S. Serke, Martin Wilhelm, Michael Hallek, Dieter Huhn, R. Kuse, Axel Hinke
Publikováno v: Blood. 98:1326-1331
Rituximab (IDEC-C2B8) is a chimeric antibody that binds to the B-cell surface antigen CD20. Rituximab has significant activity in follicular non-Hodgkin lymphomas. Much less is known about the effects in chronic lymphocytic leukemia (CLL). We have in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c9c0e39311e67ed6f9102fd48263c48e
https://doi.org/10.1182/blood.v98.5.1326
Zobrazit plný text záznamu
10
Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: Evidence from phenotyping after rituxan therapy and transfectant cell analyses
Autor: S. Serke, Dieter Huhn, Agnes J. Szczepek, Ingo Schwaner, Maya Yordanova
Publikováno v: Cytometry. 46:98-104
Numerous studies have reported that monoclonal antibody (mAb) FMC7 detects an antigen present on only a subset of circulating B lymphocytes. In particular, this mAb may distinguish typical B-cell chronic lymphocytic leukemia (FMC7 negative) from othe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3633ab9c6fa6445b056ebe3a9dd63dcb
https://doi.org/10.1002/cyto.1071
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje